CN107041928A - 一种用于治疗帕金森症的中药组合物及其制备方法 - Google Patents
一种用于治疗帕金森症的中药组合物及其制备方法 Download PDFInfo
- Publication number
- CN107041928A CN107041928A CN201710160048.2A CN201710160048A CN107041928A CN 107041928 A CN107041928 A CN 107041928A CN 201710160048 A CN201710160048 A CN 201710160048A CN 107041928 A CN107041928 A CN 107041928A
- Authority
- CN
- China
- Prior art keywords
- parts
- chinese medicine
- parkinsonism
- medicine composition
- weight
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 38
- 208000027089 Parkinsonian disease Diseases 0.000 title claims abstract description 23
- 206010034010 Parkinsonism Diseases 0.000 title claims abstract description 23
- 239000000203 mixture Substances 0.000 title claims abstract description 18
- 238000002360 preparation method Methods 0.000 title abstract description 10
- 239000000463 material Substances 0.000 claims abstract description 9
- 238000000034 method Methods 0.000 claims abstract description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 23
- 239000000284 extract Substances 0.000 claims description 19
- 238000010992 reflux Methods 0.000 claims description 8
- 238000001914 filtration Methods 0.000 claims description 6
- 239000007788 liquid Substances 0.000 claims description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 6
- 238000000605 extraction Methods 0.000 claims description 5
- 229940126678 chinese medicines Drugs 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- 239000006228 supernatant Substances 0.000 claims description 3
- 238000009472 formulation Methods 0.000 claims description 2
- 238000011282 treatment Methods 0.000 abstract description 8
- 229940079593 drug Drugs 0.000 abstract description 5
- 238000005516 engineering process Methods 0.000 abstract description 3
- 230000008569 process Effects 0.000 abstract description 3
- 241000255789 Bombyx mori Species 0.000 abstract description 2
- 240000006079 Schisandra chinensis Species 0.000 abstract description 2
- 235000013399 edible fruits Nutrition 0.000 abstract description 2
- 230000001225 therapeutic effect Effects 0.000 abstract description 2
- 244000061520 Angelica archangelica Species 0.000 abstract 1
- 241000258920 Chilopoda Species 0.000 abstract 1
- 235000001287 Guettarda speciosa Nutrition 0.000 abstract 1
- 241000361919 Metaphire sieboldi Species 0.000 abstract 1
- 241000521581 Millettia Species 0.000 abstract 1
- 244000170916 Paeonia officinalis Species 0.000 abstract 1
- 235000006484 Paeonia officinalis Nutrition 0.000 abstract 1
- 240000007164 Salvia officinalis Species 0.000 abstract 1
- 241000522620 Scorpio Species 0.000 abstract 1
- 235000005412 red sage Nutrition 0.000 abstract 1
- 239000009490 scorpio Substances 0.000 abstract 1
- 239000008280 blood Substances 0.000 description 30
- 210000004369 blood Anatomy 0.000 description 26
- 210000004185 liver Anatomy 0.000 description 19
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 18
- 230000007812 deficiency Effects 0.000 description 17
- 206010062717 Increased upper airway secretion Diseases 0.000 description 15
- 201000010099 disease Diseases 0.000 description 15
- 208000026435 phlegm Diseases 0.000 description 15
- 210000003734 kidney Anatomy 0.000 description 14
- 206010010904 Convulsion Diseases 0.000 description 13
- 230000036461 convulsion Effects 0.000 description 12
- 210000003414 extremity Anatomy 0.000 description 8
- 206010044565 Tremor Diseases 0.000 description 7
- 239000002775 capsule Substances 0.000 description 7
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 6
- 206010003549 asthenia Diseases 0.000 description 5
- 239000011800 void material Substances 0.000 description 5
- 208000002173 dizziness Diseases 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 210000003141 lower extremity Anatomy 0.000 description 4
- 210000002435 tendon Anatomy 0.000 description 4
- 230000017531 blood circulation Effects 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 229960003638 dopamine Drugs 0.000 description 3
- 206010015037 epilepsy Diseases 0.000 description 3
- 208000021760 high fever Diseases 0.000 description 3
- 210000003205 muscle Anatomy 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 239000009636 Huang Qi Substances 0.000 description 2
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 2
- 235000002789 Panax ginseng Nutrition 0.000 description 2
- 208000031971 Yin Deficiency Diseases 0.000 description 2
- 238000013019 agitation Methods 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 230000005714 functional activity Effects 0.000 description 2
- 230000036285 pathological change Effects 0.000 description 2
- 231100000915 pathological change Toxicity 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 210000001835 viscera Anatomy 0.000 description 2
- 239000002023 wood Substances 0.000 description 2
- MUKYLHIZBOASDM-UHFFFAOYSA-N 2-[carbamimidoyl(methyl)amino]acetic acid 2,3,4,5,6-pentahydroxyhexanoic acid Chemical compound NC(=N)N(C)CC(O)=O.OCC(O)C(O)C(O)C(O)C(O)=O MUKYLHIZBOASDM-UHFFFAOYSA-N 0.000 description 1
- 241000132012 Atractylodes Species 0.000 description 1
- 206010006100 Bradykinesia Diseases 0.000 description 1
- 241000522254 Cassia Species 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 241000931705 Cicada Species 0.000 description 1
- 244000205754 Colocasia esculenta Species 0.000 description 1
- 235000006481 Colocasia esculenta Nutrition 0.000 description 1
- 241000209020 Cornus Species 0.000 description 1
- 229940081615 DOPA decarboxylase inhibitor Drugs 0.000 description 1
- 241001148782 Davallia Species 0.000 description 1
- 102000015554 Dopamine receptor Human genes 0.000 description 1
- 108050004812 Dopamine receptor Proteins 0.000 description 1
- 208000035126 Facies Diseases 0.000 description 1
- 206010017577 Gait disturbance Diseases 0.000 description 1
- 235000011201 Ginkgo Nutrition 0.000 description 1
- 244000194101 Ginkgo biloba Species 0.000 description 1
- 235000008100 Ginkgo biloba Nutrition 0.000 description 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 1
- 244000303040 Glycyrrhiza glabra Species 0.000 description 1
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 description 1
- 240000006509 Gynostemma pentaphyllum Species 0.000 description 1
- 235000002956 Gynostemma pentaphyllum Nutrition 0.000 description 1
- 235000017443 Hedysarum boreale Nutrition 0.000 description 1
- 235000007858 Hedysarum occidentale Nutrition 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 208000006083 Hypokinesia Diseases 0.000 description 1
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 1
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 1
- 206010062575 Muscle contracture Diseases 0.000 description 1
- 240000005373 Panax quinquefolius Species 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 244000197580 Poria cocos Species 0.000 description 1
- 235000008599 Poria cocos Nutrition 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 244000046146 Pueraria lobata Species 0.000 description 1
- 235000010575 Pueraria lobata Nutrition 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 241001601725 Sthenias Species 0.000 description 1
- 241001533104 Tribulus terrestris Species 0.000 description 1
- 208000031975 Yang Deficiency Diseases 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- DKNWSYNQZKUICI-UHFFFAOYSA-N amantadine Chemical compound C1C(C2)CC3CC2CC1(N)C3 DKNWSYNQZKUICI-UHFFFAOYSA-N 0.000 description 1
- 229960003805 amantadine Drugs 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- 230000035568 catharsis Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 238000007596 consolidation process Methods 0.000 description 1
- 208000006111 contracture Diseases 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 239000000534 dopa decarboxylase inhibitor Substances 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 206010013781 dry mouth Diseases 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- 230000003181 encephalopathic effect Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000001947 glycyrrhiza glabra rhizome/root Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000013210 hematogenous Diseases 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 229960004502 levodopa Drugs 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 210000001259 mesencephalon Anatomy 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 210000001577 neostriatum Anatomy 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 230000001769 paralizing effect Effects 0.000 description 1
- 230000003950 pathogenic mechanism Effects 0.000 description 1
- 230000037452 priming Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 230000000862 serotonergic effect Effects 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000003393 splenic effect Effects 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 210000003523 substantia nigra Anatomy 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 210000001364 upper extremity Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/232—Angelica
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/618—Molluscs, e.g. fresh-water molluscs, oysters, clams, squids, octopus, cuttlefish, snails or slugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/62—Leeches; Worms, e.g. cestodes, tapeworms, nematodes, roundworms, earth worms, ascarids, filarias, hookworms, trichinella or taenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/63—Arthropods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/63—Arthropods
- A61K35/646—Arachnids, e.g. spiders, scorpions, ticks or mites
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/63—Arthropods
- A61K35/648—Myriapods, e.g. centipedes or millipedes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/486—Millettia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/537—Salvia (sage)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/57—Magnoliaceae (Magnolia family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/65—Paeoniaceae (Peony family), e.g. Chinese peony
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
- A61K36/704—Polygonum, e.g. knotweed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/74—Rubiaceae (Madder family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/79—Schisandraceae (Schisandra family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/894—Dioscoreaceae (Yam family)
- A61K36/8945—Dioscorea, e.g. yam, Chinese yam or water yam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/898—Orchidaceae (Orchid family)
- A61K36/8988—Gastrodia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Alternative & Traditional Medicine (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Insects & Arthropods (AREA)
- Tropical Medicine & Parasitology (AREA)
- Marine Sciences & Fisheries (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
一种用于治疗帕金森症的中药组合物及其制备方法,涉及帕金森症的治疗技术领域,由以下重量份的中药原料制得:当归5‑25份、白芍5‑25份、丹参10‑30份、白芷1‑20份、萆薢30‑50份、地龙1‑20份、僵蚕1‑10份、蜈蚣1‑10份、珍珠母1‑20份、全蝎1‑20份、石楠叶20‑40份、鸡血藤10‑30份、钩藤1‑20份、天麻5‑25份、制首乌1‑20份、五味子1‑20份。本发明通过合理的病机辩治,合理选配十六味中药配伍,优选每味中药的加入比例,从而使制备的中药组合物,对帕金森症具有良好的治疗效果,且治愈率高。
Description
技术领域
本发明涉及帕金森症的治疗技术领域,具体是涉及一种用于治疗帕金森症的中药组合物及其制备方法。
背景技术
帕金森病(Parkinson disease,PD)是一种常见的神经系统变性疾病,老年人多见,平均发病年龄为60岁左右,40岁以下起病的青年帕金森病较少见。我国65岁以上人群PD的患病率大约是1.7%。大部分帕金森病患者为散发病例,仅有不到10%的患者有家族史。帕金森病最主要的病理改变是中脑黑质多巴胺(dopamine,DA)能神经元的变性死亡,由此而引起纹状体DA含量显著性减少而致病。
帕金森病是老年人常见的神经系统退行性疾病,其特征表现是静止性震颤、肌强直、运动迟缓和姿势步态障碍。西医应用左旋多巴及外周多巴脱羧酶抑制剂、多巴胺受体激动剂等治疗已取得明显进步,但久治效果不易巩固,不易控制其自然发展。
同时,通过中药治疗帕金森病,经过多年的发展,也已经出现了较多的药物可供患者使用,例如,中国专利CN 103393809A公开了一种治疗帕金森的中药,由下述重量份配比的原料制成的:红参30-100份、白术30-50份、茯苓30-50份、当归30-80份、黄芪100-400份、升麻50-80份、柴胡50-80份、葛根50-80份、肉桂50-100份、苍术50-150份、吴芋30-100份、补骨脂100-200份、骨碎补200-250份、橘红40-100份、炙甘草30-50份。该中药本着温土升阳为目的,使清阳升而脑有所养。另外,中国专利CN 104800604A公开了一种治疗帕金森的中药配方,由以下重量份数的中药原料配制而成:天麻20-30份、钩藤20-30份、熟地15-20份、山萸肉10-15份、红参5-10份、黄芪5-10份、茺蔚子8-12份、蝉蜕6-12份、蒺藜15-20份、银杏叶6-8份、刺五加6-8份、五味子6-10份、蛞蝓10-15份、绞股蓝8-13份、茯神7-10份、仙茅6-11份和僵蚕9-15份,通过中药的调理,益气活血、平肝息风、滋肝肾之阴、揉筋息风,治疗帕金森,治愈率高。
发明内容
为了解决上述技术问题,本发明基于血脉瘀滞、筋急风动病理机制,对帕金森病进行深入研究,从而获得了一种用于治疗帕金森症的中药组合物,对帕金森症的治愈率高。
为了实现上述目的,本发明所采用的技术方案如下:
一种用于治疗帕金森症的中药组合物,由以下重量份的中药原料制得:
优选地,用于治疗帕金森症的中药组合物,由以下重量份的中药原料制得:
进一步优选地,用于治疗帕金森症的中药组合物,由以下重量份的中药原料制得:
一种用于治疗帕金森症的中药组合物的制备方法,步骤如下:
1)、将十六味中药合并,用75%乙醇回流提取二次,第一次加10倍重量的75%乙醇,回流提取2h;第二次加8倍重量的75%乙醇,回流提取1.5h;合并醇提液,滤过,回收乙醇;
2)、药渣加8倍重量的水,煎煮提取1h,滤过,静置沉淀48h,吸取上清液,同醇提液合并减压浓缩至比重为1.10的流浸膏;
3)、向流浸膏中加入药用辅料,再制成药剂学中的各种剂型。
发明人从事临床教学及科研工作40余载,对帕金森症等有较深入的研究,发明人认为,帕金森病的突出病症是震颤,此为肝风内动之症,其本在于肝肾亏虚。《素问》曰:“诸风掉眩,皆属于肝。”肝风之起,乃由肝肾亏虚,水不涵木,虚阳化风所致。从发病年龄看,本病多发于老年人,40岁以下发病者少见。《证治准绳》曰:“此病壮年鲜有,中年以后乃有之,老年尤多,夫年老阴血不足,少水不能制肾火,极为难治。”原因有二:①生理性虚衰。《素问》谓“年四十而阴气自半也”,人过中年,肝肾阴气自然衰减,形体衰败,若摄养不慎,极易造成肝肾亏虚;②病理性肝肾虚损。因高年多病重叠,或久病及肾,致使肝肾交亏。肝藏血而主筋,肾藏精而主脑髓,肾虚则髓减,脑髓失养则神失所荣,身失主持而失灵。故本病阴虚者多见,但久病阴虚,阴损及阳,故又可兼见阴阳两虚。此外,因气虚失运,血不养筋,血虚生风,气血两虚也不少见。而五志化火,食积化火,外邪内袭等,往往都是引动肝风的重要因素。
另外,帕金森症除震颤外,又并见麻痹与强直。麻痹者,中医早有“风麻病温木”之说,诚如《张氏医通》:“麻则属痰属虚,木则全属湿痰死血。”强直者,《内经》中已阐明,“诸暴强直,皆属于风”,而强直之因,《医学原理》谓“有因痰火塞窒经隧”,“有气血不能引导”,致使血与津液无以荣养筋脉所致。痰由湿所化,多因素体肥胖,痰湿过盛,或过食肥甘,大量饮酒,痰湿内蕴;或饮食劳倦,内伤脾胃,水湿停蓄所致。《素问》说“诸痉项强,皆属于湿”,痰湿内阻,经气不畅,以致静脉失养而僵硬强直,手不持物,动作迟缓、振掉。痰与风相挟,风痰阻络,使诸症更重。瘀乃由气滞或气虚而成。肝肾阴虚,木失所养,疏泄失权,气机不畅致瘀;或因气虚失运,血少而涩,血行迟缓而瘀阻脉道。此外,情志内郁,痰湿积滞等,也可影响气的疏通而形成局部或全身的气机不畅或阻滞,以致产生血瘀。瘀血阻滞,脉道不畅,血行不畅,筋脉失蠕而手足颤动,屈伸不利,此即“血瘀生风”。在肝肾亏虚的基础上,痰瘀内生,阻滞脑络,更加剧了内风暗动,在本病与他病重叠时痰瘀交阻尤为突出。
帕金森病多为本虚标实之证,肝风内动为病之标,脏腑气血功能失调为病之本。肝肾阴虚,气血不足为病之虚;风、痰、瘀为病之实。本虚标实,虚实错杂。辩证首当明辨虚实、标本之主次。临床缩减肝肾阴虚者居多,约半数以上。标本之间密切联系,风、痰、瘀可因虚而生,诸邪又进一步影响阴血对筋脉的濡养。风、痰、瘀之间也相互联系,可互相转化,临床虚实可见,各种症候错杂,临证时应详审病机,辩证治疗。
临证用药应治实勿忘补其虚,补虚尚应祛其邪。补虚以滋补肝肾,益气养血,攻邪以化痰除湿,活血化瘀为主,祛邪宜十去其六即可,以免太过伤正。并可于原治法加入熄风止痉之品增强疗效,所谓颤振属风,息风为先,不论何种证型,均应在治本的基础上运用平肝熄风之法。震颤日久,则可加入虫类药以加强其搜风通络、熄风止痉之效。年高病久,治宜缓图。因老年体表加之颤振日久,脏腑气血失调,病理变化复杂,欲速反招致诸多变证,只宜图缓,循序渐进。临证用药不易过于滋腻,否则易致本病胶着难解。知常达变,最宜变通。依据其病情的增减进退而即使调整治法方药,从而治法有常有变,灵活准确。帕金森病患者无论何种证候,大都兼有瘀血阻络之象。瘀血既是一种病理产物,也是引起加重颤振的重要因素,因此在治疗上应重视活血化瘀。
本发明通过合理的病机辩治,合理选配十六味中药配伍,优选每味中药的加入比例,从而使制备的中药组合物,对帕金森症具有良好的治疗效果,且治愈率高。
具体实施方式
以下结合实施例对本发明作进一步的说明。
实施例1
一、一种用于治疗帕金森症的抗颤止痉胶囊,有效成分由以下重量份的中药原料制得:
二、一种用于治疗帕金森症的抗颤止痉胶囊的制备方法步骤如下:
1)、将十六味中药合并,用75%乙醇回流提取二次,第一次加10倍重量的75%乙醇,回流提取2h;第二次加8倍重量的75%乙醇,回流提取1.5h;合并醇提液,滤过,回收乙醇;
2)、药渣加8倍重量的水,煎煮提取1h,滤过,静置沉淀48h,吸取上清液,同醇提液合并减压浓缩至比重为1.10的流浸膏;
3)、将流浸膏喷雾干燥,加入药用辅料;
4)、装入胶囊,制得用于治疗帕金森症的抗颤止痉胶囊,规格为0.4g/粒。
三、用于治疗帕金森症的抗颤止痉胶囊的临床典型病例
某男,72岁,因渐进性四肢抖动,肢体僵直,动作缓慢6年入院(安徽中医药大学第一附属医院),2004年在日常生活中出现右手抖动,静止时明显,紧张时加重,持物不灵,渐渐发展至右下肢,逐渐延伸及左手、左下肢,动作缓慢,肢体僵直。在外院诊断为帕金森,一直以多巴胺肼、金刚烷胺、苯海索等药物治疗,初期疗效尚可,但逐渐疗效减退,肢体抖动明显,翻身、行动困难,而在2009年8月15日求治于我院脑病科。
初诊:表情呆板,面色晦暗,言语含糊,行动困难,家人搀扶,四肢静止性震颤明显,以右侧为甚,四肢肌张力齿轮样增高。怕热多汗,心烦口干咽燥,大便干结,舌质暗红,脉弦细数。证属肝肾阴虚,兼气滞血瘀。治以补益肝肾,育阴熄风,养血化瘀。主治肝血补足,筋脉失养,瘀血内阻,虚风内动。遂采用抗颤止痉胶囊治疗。
二诊(2009年8月29日):服用抗颤止痉胶囊14天,病人自诉肢体抖动、双下肢僵硬感较前好转,出汗减少。
三诊(2009年9月12日):下肢行走明显改善,右上肢抖动、四肢僵直减轻,精神转佳,大便正常,口干消失。后随访症状基本控制,病情稳定。
实施例2
制备方法同实施例1。
实施例3
制备方法同实施例1。
实施例4
制备方法同实施例1。
实施例5
制备方法同实施例1。
以上内容仅仅是对本发明的构思所作的举例和说明,所属本技术领域的技术人员对所描述的具体实施例做各种各样的修改或补充或采用类似的方式替代,只要不偏离发明的构思或者超越本权利要求书所定义的范围,均应属于本发明的保护范围。
Claims (4)
1.一种用于治疗帕金森症的中药组合物,其特征在于,由以下重量份的中药原料制得:
2.如权利要求1所述的用于治疗帕金森症的中药组合物,其特征在于,由以下重量份的中药原料制得:
3.如权利要求2所述的用于治疗帕金森症的中药组合物,其特征在于,由以下重量份的中药原料制得:
4.一种制备如权利要求1或2或3所述中药组合物的方法,其特征在于,步骤如下:
1)、将十六味中药合并,用75%乙醇回流提取二次,第一次加10倍重量的75%乙醇,回流提取2h;第二次加8倍重量的75%乙醇,回流提取1.5h;合并醇提液,滤过,回收乙醇;
2)、药渣加8倍重量的水,煎煮提取1h,滤过,静置沉淀48h,吸取上清液,同醇提液合并减压浓缩至比重为1.10的流浸膏;
3)、向流浸膏中加入药用辅料,再制成药剂学中的各种剂型。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710160048.2A CN107041928A (zh) | 2017-03-17 | 2017-03-17 | 一种用于治疗帕金森症的中药组合物及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710160048.2A CN107041928A (zh) | 2017-03-17 | 2017-03-17 | 一种用于治疗帕金森症的中药组合物及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN107041928A true CN107041928A (zh) | 2017-08-15 |
Family
ID=59544694
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201710160048.2A Pending CN107041928A (zh) | 2017-03-17 | 2017-03-17 | 一种用于治疗帕金森症的中药组合物及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN107041928A (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108743822A (zh) * | 2018-09-04 | 2018-11-06 | 刘露 | 一种治疗帕金森病的中药油 |
CN111632112A (zh) * | 2020-06-23 | 2020-09-08 | 西安岐奥丰医疗发展有限公司 | 熄风通络制剂及其制备方法 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20170022715A (ko) * | 2015-08-21 | 2017-03-02 | 경희대학교 산학협력단 | 조현병 관련 정신 장애의 예방 또는 치료용 조성물 |
-
2017
- 2017-03-17 CN CN201710160048.2A patent/CN107041928A/zh active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20170022715A (ko) * | 2015-08-21 | 2017-03-02 | 경희대학교 산학협력단 | 조현병 관련 정신 장애의 예방 또는 치료용 조성물 |
Non-Patent Citations (3)
Title |
---|
周义先等: "抗震止痉胶囊Ⅱ号联合美多巴治疗帕金森病的临床研究", 《中西医结合心脑血管病杂志》 * |
汪瀚等: "鲍远程治疗帕金森病的经验", 《中医药临床杂志》 * |
滕书文等: "定震汤治疗帕金森病32例疗效观察", 《浙江中医学院学报》 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108743822A (zh) * | 2018-09-04 | 2018-11-06 | 刘露 | 一种治疗帕金森病的中药油 |
CN111632112A (zh) * | 2020-06-23 | 2020-09-08 | 西安岐奥丰医疗发展有限公司 | 熄风通络制剂及其制备方法 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN104645132A (zh) | 一种治疗糖尿病肾病的中药组合物、制备方法、中药制剂及应用 | |
CN101293065B (zh) | 一种用于预防和治疗糖尿病的生物中成药 | |
CN107041928A (zh) | 一种用于治疗帕金森症的中药组合物及其制备方法 | |
CN103585482A (zh) | 一种治疗帕金森病的中药组合物及其制备方法 | |
CN106236875A (zh) | 一种清肝明目的中药组合物及其制备方法 | |
CN105362778A (zh) | 一种治疗反流性胃炎的中药组合物及其制备方法 | |
CN102772569A (zh) | 一种保健药酒 | |
CN102600351B (zh) | 一种治疗皮肤瘙痒症的中药 | |
CN104689218A (zh) | 一种治疗脂肪肝的中药组合物 | |
CN105381388A (zh) | 一种治疗胃部不适的中药组合物及其制备方法 | |
CN102552677B (zh) | 黄地安消胶囊及其制备方法 | |
CN104474103A (zh) | 一种天然植物降糖剂及其制备方法 | |
CN104705634A (zh) | 一种保护健康的灵芝保健品 | |
CN103520693B (zh) | 一种治疗心肺气虚证型胸痹心痛的中药 | |
CN105395695A (zh) | 一种治疗胃部疼痛的中药组合物及其制备方法 | |
CN106138533A (zh) | 一种治疗胃胀痛的中药组合物及其制备方法 | |
CN106074981A (zh) | 一种治疗浅表性胃炎的中药组合物及其制备方法 | |
CN105663416A (zh) | 一种治疗心血瘀阻型胸痹的中药组合物及其制备方法 | |
CN105012709B (zh) | 用于痿症的补肾温阳丸 | |
CN104705637A (zh) | 一种枸杞桑椹保健组合物 | |
CN108785586A (zh) | 一种用于辅助治疗运动神经元病的中药组合物及应用 | |
CN104547194A (zh) | 一种治疗乳腺增生的中药组合物 | |
CN103638150B (zh) | 治疗高血压的药物 | |
CN114848784A (zh) | 一种用于治疗癌症的中药组合物 | |
CN110368437A (zh) | 一种清除过敏性紫癜的中药组合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20170815 |
|
RJ01 | Rejection of invention patent application after publication |